Alpha DNA Investment Management LLC Acquires Shares of 5,098 Blueprint Medicines Co. (NASDAQ:BPMC)

Alpha DNA Investment Management LLC bought a new position in Blueprint Medicines Co. (NASDAQ:BPMC) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 5,098 shares of the biotechnology company’s stock, valued at approximately $445,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of BPMC. Sanctuary Advisors LLC bought a new position in shares of Blueprint Medicines in the third quarter valued at approximately $202,000. Synovus Financial Corp boosted its stake in shares of Blueprint Medicines by 4.0% during the third quarter. Synovus Financial Corp now owns 24,047 shares of the biotechnology company’s stock valued at $2,224,000 after purchasing an additional 922 shares during the period. Franklin Resources Inc. grew its stake in shares of Blueprint Medicines by 0.7% in the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock worth $3,259,000 after purchasing an additional 265 shares during the last quarter. Exome Asset Management LLC bought a new stake in Blueprint Medicines in the third quarter valued at $3,395,000. Finally, Empirical Asset Management LLC purchased a new position in shares of Blueprint Medicines during the fourth quarter valued at about $2,348,000.

Insider Activity

In other news, COO Christina Rossi sold 2,274 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $110.14, for a total transaction of $250,458.36. Following the transaction, the chief operating officer now directly owns 67,109 shares in the company, valued at approximately $7,391,385.26. This trade represents a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kate Haviland sold 1,446 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total value of $159,407.04. Following the sale, the chief executive officer now owns 149,378 shares of the company’s stock, valued at $16,467,430.72. This trade represents a 0.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 24,358 shares of company stock worth $2,583,187. Company insiders own 4.21% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on BPMC. Wedbush reiterated an “outperform” rating and issued a $128.00 price objective on shares of Blueprint Medicines in a report on Wednesday. Wolfe Research began coverage on Blueprint Medicines in a research report on Tuesday, March 18th. They issued an “outperform” rating on the stock. StockNews.com lowered shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Monday, March 3rd. Stephens reissued an “overweight” rating and issued a $140.00 target price on shares of Blueprint Medicines in a report on Thursday, January 2nd. Finally, Scotiabank initiated coverage on Blueprint Medicines in a research note on Friday, March 7th. They set a “sector outperform” rating and a $150.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $124.95.

Blueprint Medicines Stock Performance

Shares of NASDAQ:BPMC opened at $84.62 on Friday. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. The company has a market capitalization of $5.41 billion, a price-to-earnings ratio of -78.35 and a beta of 0.75. Blueprint Medicines Co. has a 12 month low of $73.04 and a 12 month high of $121.90. The firm’s 50-day moving average is $88.61 and its 200 day moving average is $93.22.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Research analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.